Lessons from the Polio Endgame: Overcoming the Failure to Vaccinate and the Role of Subpopulations in Maintaining Transmission

Journal of Infectious Diseases

Volumn 216, Issue , 2017, Pages S176-S182

  Thompson, Kimberly M ^a,b   Duintjer Tebbens, Radboud J ^a  

^a Kid Risk Inc   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

eradication; heterogeneity; Polio; transmission

Indexed keywords

ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

ADOLESCENT; ARTICLE; CHILD; DISEASE ERADICATION; HEALTH CARE ACCESS; HUMAN; IMMUNE DEFICIENCY; INFANT; INFECTION RESISTANCE; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROGRAM EVALUATION; RISK MANAGEMENT; VACCINATION; VACCINE FAILURE; VIRUS TRANSMISSION; BIOLOGICAL MODEL; EPIDEMIC; GLOBAL HEALTH; HEALTH CARE DELIVERY; IMMUNIZATION; IMMUNOLOGY; NEWBORN; PATHOGENICITY; PRESCHOOL CHILD; STATISTICAL MODEL; TRANSMISSION; VIROLOGY;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; GLOBAL HEALTH; HEALTH SERVICES ACCESSIBILITY; HUMANS; IMMUNIZATION; INFANT; INFANT, NEWBORN; MODELS, BIOLOGICAL; MODELS, STATISTICAL; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL;

EID: 85019255435     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix108     Document Type: Article

References (75)

1. UNICEF. RFP-DAN-2016-502330 Bivalent Oral Polio Vaccines. Available at: https://www.unicef.org/supply/index-94239.html. Accessed 13 January 2017
2. Thompson KM, Pallansch MA, Tebbens RJ, Wassilak SG, Cochi SL. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal 2013; 33:647-63
3. Barrett S. Polio eradication: strengthening the weakest links. Health Aff (Millwood) 2009; 28:1079-90
4. Etsano A, Damisa E, Shuaib F, et al. Environmental isolation of circulating vaccine-derived poliovirus after interruption of wild poliovirus transmission-Nigeria, 2016. MMWR Morb Mortal Wkly Rep 2016; 65:770-3
5. Thompson KM, Tebbens RJ. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation. Expert Rev Vaccines 2012; 11:449-59
6. World Health Organization. Meeting of the strategic advisory group of experts on immunization, April 2012-conclusions and recommendations, polio eradication. Wkly Epidemiol Rec 2012; 87:204-7
7. Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis 2014; 210:475-84
8. World Health Organization. Global Polio Eradication Initiative-List of wild poliovirus by country. http://www.polioeradication.org/Dataandmonitoring/ Poliothisweek/Wildpolioviruslist.aspx. Accessed 18 January 2017
9. Kew OM, Cochi SL, Jafari HS, et al. Possible eradication of wild poliovirus type 3-worldwide, 2012. Morb Mort Wkly Rep 2014; 63:1031-3
10. World Health Organization. Summary of poliovirus circulation in 2016-Pakistan (27 December 2016). http://www.who.int/csr/don/27-december-2016-polio-pakistan/ en/. Accessed 13 January 2017
11. Weiss WM, Winch PJ, Burnham G. Factors associated with missed vaccination during mass immunization campaigns. J Health Popul Nutr 2009; 27:358-67
12. Tauil MD, Sato APS, Waldman EA. Factors associated with incomplete or delayed vaccination across countries: a systematic review. Vaccine 2016; 34:2635-43
13. Chaturvedi S, Dasgupta R, Adhish V, et al. Deconstructing social resistance to pulse polio campaign in two North Indian districts. Indian Pediatr 2009; 46:963-74
14. Khowaja AR, Khan SA, Nizam N, Omer SB, Zaidi A. Parental perceptions surrounding polio and self-reported non-participation in polio supplementary immunization activities in Karachi, Pakistan: a mixed methods study. Bull World Health Organ 2012; 90:822-30
15. Ado JM, Etsano A, Shuaib F, et al. Progress toward poliomyelitis eradication in Nigeria. J Infect Dis 2014; 210 Suppl 1:40-9
16. Bugvi AS, Rahat R, Zakar R, et al. Factors associated with non-utilization of child immunization in Pakistan: evidence from the demographic and health Survey 2006-07. BMC Public Health 2014; 14:7
17. Michael CA, Ashenafi S, Ogbuanu IU, et al.; OPV Campaign Missed Children Study Team. An evaluation of community perspectives and contributing factors to missed children during an oral polio vaccination campaign-Katsina State, Nigeria. J Infect Dis 2014; 210 Suppl 1:131-5
18. Simpson DM, Sadr-Azodi N, Mashal T, et al. Polio eradication initiative in Afghanistan, 1997-2013. J Infect Dis 2014; 210:S162-72
19. Fekadu L, Okeibunor J, Nsubuga P, Kipela JM, Mkanda P, Mihigo R. Reaching the unreached with polio vaccine and other child survival interventions through partnership with military in Angola. Vaccine 2016; 34:5155-8
20. Gali E, Mkanda P, Banda R, et al. Revised household-based microplanning in polio supplemental immunization activities in Kano State, Nigeria. 2013-2014. J Infect Dis 2016; 213:73-8
21. Ghafoor S, Sheikh N. Eradication and current status of poliomyelitis in pakistan: ground realities. J Immunol Res 2016; 2016:6837824
22. ConynvanSpaendonck MAE, Oostvogel PM, vanLoon AM, vanWijngaarden JK, Kromhout D. Circulation of poliovirus during the poliomyelitis outbreak in the Netherlands in 1992-1993. Am J Epidemiol 1996; 143:929-35
23. Smith PJ, Chu SY, Barker LE. Children who have received no vaccines: who are they and where do they live? Pediatrics 2004; 114:187-95
24. Kisjes KH, Duintjer Tebbens RJ, Wallace GS, et al. Individual-based modeling of potential poliovirus transmission in connected religious communities in North America with low uptake of vaccination. J Infect Dis 2014; 210:424-33
25. Derrough T, Salekeen A. Lessons learnt to keep Europe polio-free: a review of outbreaks in the European Union, European Economic Area, and candidate countries, 1973 to 2013. Eurosurveillance 2016; 21:51-9
26. Bham SQ, Saeed F, Shah MA. Routine immunization in children and unsatisfactory polio campaigns; a cross sectional survey conducted at Darul Sehat Hospital, Karachi. Ann Abbasi Shaheed Hosp Karachi Med Dent Coll 2016; 21:29-36
27. Tebbens RJ, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal 2006; 26:1471-505
28. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM. An economic analysis of poliovirus risk management policy options for 2013-2052. BMC Infect Dis 2015; 15:389
29. Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. BMC Infect Dis 2015; 15:379
30. Duintjer Tebbens RJ, Hampton LM, Thompson KM. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation. BMC Infect Dis 2016; 16:231
31. Duintjer Tebbens RJ, Hampton LM, Thompson KM. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use. BMC Infect Dis 2016; 16:237
32. Thompson KM, Duintjer Tebbens RJ. Lessons from globally-coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes. J Infect Dis 2017; 215 (suppl 4):168-175
33. Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal 2013; 33:703-49
34. Duintjer Tebbens RJ, Kalkowska DA, Wassilak SG, Pallansch MA, Cochi SL, Thompson KM. The potential impact of expanding target age groups for polio immunization campaigns. BMC Infect Dis 2014; 14:45
35. Thompson KM, Kalkowska DA, Duintjer Tebbens RJ. Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses. Vaccine 2015; 33:1568-77
36. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in two highrisk areas in northern India. J Infect Dis 2014; 210:398-411
37. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in the highrisk area of northwest Nigeria. J Infect Dis 2014; 210:412-23
38. Duintjer Tebbens RJ, Pallansch MA, Wassalik SGF, Cochi SL, Thompson KM. Combinations of quality and frequency of immunization activities to stop and prevent poliovirus transmission in the high-risk area of northwest Nigeria. PLoS One 2015; 10:e0130123
39. Kalkowska DA, Duintjer Tebbens RJ, Grotto I, et al. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis 2015; 211:1800-12
40. Thompson KM, Wallace GS, Tebbens RJ, et al. Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. Public Health Rep 2012; 127:23-37
41. Tebbens RJD, Kalkowska DA, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM. The potential impact of expanding target age groups for polio immunization campaigns. BMC Infect Dis 2014; 14:17
42. Blake IM, Martin R, Goel A, et al. The role of older children and adults in wild poliovirus transmission. Proc Natl Acad Sci U S A 2014; 111:10604-9
43. Wagner BG, Behrend MR, Klein DJ, Upfill-Brown AM, Eckhoff PA, Hu H. Quantifying the impact of expanded age group campaigns for polio eradication. PLoS One 2014; 9:14
44. World Health Organization. Polio in the Syrian Arab Republic. http://polioeradication. org/news-post/polio-in-The-syrian-arab-republic/. Accessed 13 January 2017
45. Grassly NC, Wenger J, Durrani S, et al. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet 2007; 369:1356-62
46. Duintjer Tebbens RJ, Pallansch MA, Kim JH, et al. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal 2013; 33:680-702
47. Pons-Salort M, Burns CC, Lyons H, et al. Preventing vaccine-derived poliovirus emergence during the polio endgame. PLoS Pathog 2016; 12:e1005728
48. Centers for Disease Control and Prevention. Resurgence of wild poliovirus type 1 transmission and consequences of importation-21 previously polio-free countries, 2002-2005. MMWR Morb Mortal Wkly Rep 2006; 55:145-50
49. Duintjer Tebbens RJ, Hampton LM, Wassilak SG, Pallansch MA, Cochi SL, Thompson KM. Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation. J Vaccin Vaccination 2016; 7:doi: 10.4172/2157-7560.1000340
50. Duintjer Tebbens RJ, Thompson KM. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis 2014; 210:485-97
51. Duintjer Tebbens RJ, Thompson KM. Costs and benefits of including inactivated in addition to oral poliovirus vaccine in outbreak response after cessation of oral poliovirus vaccine use. Med Decis Making Policy Pract 2017; 2(1), doi:10.1177/2381468317697002
52. Weil M, Shulman LM, Heiman S, et al. Prolonged excretion of type-2 poliovirus from a primary immune deficient patient during the transition to a type-2 poliovirus-free world, Israel, 2016. Euro Surveill 2016; 21:30408
53. Duintjer Tebbens RJ, Thompson KM. Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy. Epidemiol Infect 2017; 145:217-26
54. Minor PD. Eradication and cessation of programmes. Br Med Bull 2002; 62:213-24
55. Minor P. Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication. Vaccine 2009; 27:2649-52
56. Minor P. The polio endgame. Hum Vaccin Immunother 2014; 10:2106-8
57. Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis 2014; 210(Suppl 1):283-93
58. Halsey NA, Pinto J, Espinosa-Rosales F, et al.; the Polio Project Team. Search for polio virus carriers among people with primary immune deficiency diseases, United States, Mexico, Brazil and United Kingdom: Bulletin of the World Health Organization, 2004; 82(1):3-8
59. Kew OM. Reaching the last one per cent: progress and challenges in global polio eradication. Curr Opin Virol 2012; 2:188-98
60. Vaz RG, Mkanda P, Banda R, et al. The role of the polio program infrastructure in response to Ebola virus disease outbreak in Nigeria 2014. J Infect Dis 2016; 213:S140-6
61. Bhutta ZA. Infectious disease: polio eradication hinges on child health in Pakistan. Nature 2014; 511:285-7
62. World Health Organization. Responding to a poliovirus event and outbreak-Part 2: Protocol for poliovirus type http://polioeradication.org/wp-content/ uploads/2016/09/Responding-to-A-poliovirus-event-and-outbreak-SOPs-Part-2-Protocol-for-PV-Type-2-EN.pdf. Accessed 28 November 2016
63. Duintjer Tebbens RJ, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infect Dis 2016; 16:137
64. Sutter RW, John TJ, Jain H, et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet 2010; 376:1682-8
65. Estívariz CF, Anand A, Gary HE Jr, et al. Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial. Lancet Infect Dis 2015; 15:898-904
66. Sutter RW, Bahl S, Deshpande JM, et al. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial. Lancet 2015; 386:2413-21
67. Anand A, Zaman K, Estívariz CF, et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial. Vaccine 2015; 33:6816-22
68. Asturias EJ, Bandyopadhyay AS, Self S, et al.; Latin American IPV001BMG Study Group. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Lancet 2016; 388:158-69
69. Thompson KM, Duintjer Tebbens RJ. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission. BMC Infect Dis 2015; 15:376
70. Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Thompson KM. Modeling undetected live poliovirus circulation after apparent interruption of transmission: Implications for surveillance and vaccination. BMC Infect Dis 2015; 15:66
71. Thompson KM. Polio endgame management: focusing on performance with or without inactivated poliovirus vaccine. Lancet 2014; 384:1480-2
72. Tegegne SG, MKanda P, Yehualashet YG, et al. Implementation of a systematic accountability framework in 2014 to improve the performance of the Nigerian Polio Program. J Infect Dis 2016; 213:S96-100
73. Mansour E, Aylward RB, Cummings F. Integrated disease control initiatives: polio eradication and neonatal tetanus elimination in Egypt. J Infect Dis 1997; 175:S277-80
74. Banerjee K, Hlady WG, Andrus JK, Sarkar S, Fitzsimmons J, Abeykoon P. Poliomyelitis surveillance: the model used in India for polio eradication. Bull World Health Organ 2000; 78:321-9
75. Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat. World population prospects. The 2015 revision. United Nations: New York, NY, 2016; Volume I: Comprehensive tables. 2015. Report ST/ ESA/SER.A/379